Mark Pamer, DO
Pulmonary Disease · Port Saint Lucie, FLNPI 1184824542
Payments from drug & device makers
Across 1,298 payments — averaging $221.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mylan Specialty L.p.$187K
- AstraZeneca$24K
- United Therapeutics Corporation$17K
- GSK$14K
- Viatris Specialty LLC$11K
- Grifols USA, LLC$10K
- plus $25K from 49 others
What the payments were for
- Consulting fees$66,00326%
- Speaking & faculty fees$150,03058%
- Travel & lodging$10,1874%
- Food & beverage$30,22212%
- Education$7720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$287,133 in reported general payments places this provider in the 90th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 789 | $795,681 |
| OfevNintedanib Esylate | 52 | $754,456 |
| OpsumitMacitentan | 43 | $541,468 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 16 | $250,664 |
| Breo ElliptaFluticasone/Vilanterol | 312 | $180,052 |
| Dupixent SyringeDupilumab | 37 | $156,011 |
| AdempasRiociguat | 11 | $155,977 |
| TezspireTezepelumab-Ekko | 35 | $147,422 |
| NuzyraOmadacycline Tosylate | 14 | $146,530 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 129 | $142,050 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 187 | $135,528 |
| Ambrisentan | 38 | $121,817 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 177 | $118,379 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $72,283 |
| EliquisApixaban | 34 | $38,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy, Arnuity Ellipta | $13,782 | $1,114,4401,350 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Combivent Respimat, Spiriva Respimat | $1,334 | $917,132274 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $2,580 | $541,46843 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $24,389 | $298,405189 claims |
| Grifols USA, LLCProlastin C | $10,211 | $250,66416 claims |
| BayerAdempas | $194 | $155,97711 claims |
| Paratek Pharmaceuticals, Inc.Nuzyra | $266 | $146,53014 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $1,273 | $72,28313 claims |
| PfizerEliquis | $945 | $38,50834 claims |
| Johnson & JohnsonXarelto | $134 | $6,49012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Port Saint Lucie
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.